Home › Companies › ARBUTUS BIOPHARMA CORP. › 2024-2025
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and ARBUTUS BIOPHARMA CORP.’s Form 8-K, filed May 23, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of May 21, 2025: 7 items on ARBUTUS BIOPHARMA CORP.’s Form 8-K, filed May 23, 2025: 2 approved · 5 passed (calculated).
No notable dissent.
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Proxy season: 2023-2024 2024-2025 2025-2026
Activist investors: Two Seas Capital LP (13F, 4.1%, as of September 30, 2026) · Rubric Capital (13F, 1.7%, as of September 30, 2026)
Explore ARBUTUS BIOPHARMA CORP. in the interactive database Compare manager voting policies
These tallies are ARBUTUS BIOPHARMA CORP.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 23, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Lindsay Androski, JD, MBA, CFA | 123,784,223 | -- | -- | 6,331,634 | 28,231,130 | 95% | Passed (calculated) | — |
| Elect Director: Robert Alan Beardsley | 124,837,983 | -- | -- | 5,277,874 | 28,231,130 | 96% | Passed (calculated) | — |
| Elect Director: Joseph Bishop | 122,059,590 | -- | -- | 8,056,267 | 28,231,130 | 94% | Passed (calculated) | — |
| Elect Director: Matthew Gline | 122,656,045 | -- | -- | 7,459,812 | 28,231,130 | 94% | Passed (calculated) | — |
| Elect Director: Anuj Hasija | 124,821,361 | -- | -- | 5,294,496 | 28,231,130 | 96% | Passed (calculated) | — |
| 2. Approved, by non-binding advisory vote, the compensation of the Company's named executive officers as disclosed in the Company's Management Proxy Circular and Proxy Statement for the Meeting filed with the Securities and Exchange Commission on April 4, 2025 | 122,791,749 | 6,976,561 | 347,547 | -- | 28,231,130 | 95% | Approved | — |
| 3. To approve the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025 | 157,702,833 | 486,002 | 158,152 | -- | -- | 99.7% | Approved | — |
Source: ARBUTUS BIOPHARMA CORP., Form 8-K, filed with the SEC on May 23, 2025 — read the filing on EDGAR.
See voting trends for Health Care companies, 2024-2025: shareholder support by sector and by company size.
137 asset managers disclosed a vote on at least one ARBUTUS BIOPHARMA CORP. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 3 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Description as filed by funds: To elect five (5) director nominees named in the Proxy Statement/Circular, each to serve until the 2026 Annual General Meeting of Shareholders or until his or her qualified successor has been duly elected or appointed: Anuj Hasija
ARBUTUS BIOPHARMA CORP.’s own tally for this item (“Elect Director: Anuj Hasija”): 124,821,361 for, 5,294,496 withheld, per its Form 8-K filed May 23, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 36 asset managers below reported 27,883,253 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 8,631,006 | 0 | 0 | 0 | For |
| Morgan Stanley | 6,930,243 | 0 | 0 | 0 | For |
| BlackRock | 5,196,383 | 0 | 0 | 0 | For |
| Fidelity | 2,236,842 | 0 | 0 | 0 | For |
| Equitable | 1,452,524 | 0 | 0 | 0 | For |
| Charles Schwab | 1,196,192 | 0 | 0 | 0 | For |
| State Street | 643,580 | 0 | 0 | 0 | For |
| Aberdeen | 342,379 | 0 | 0 | 0 | For |
| TIAA | 311,173 | 0 | 0 | 0 | For |
| Lincoln Financial | 195,576 | 0 | 0 | 0 | For |
| Global X | 87,217 | 0 | 0 | 0 | For |
| Goldman Sachs | 76,152 | 0 | 0 | 0 | For |
| Northern Trust | 75,333 | 0 | 0 | 0 | For |
| ProShares | 59,347 | 0 | 0 | 0 | For |
| John Hancock | 55,637 | 0 | 0 | 0 | For |
| Pacific Life | 48,221 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 43,209 | 0 | 0 | 0 | For |
| Voya | 40,720 | 0 | 0 | 0 | For |
| Invesco | 34,997 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 32,553 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 32,123 | 0 | 0 | 0 | For |
| DWS | 21,153 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 21,061 | 0 | 0 | 0 | For |
| Nationwide | 21,049 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 17,801 | 0 | 0 | 0 | For |
Showing the 25 largest of 36 asset managers. All 36 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
94% Majority: yes · of votes cast
Description as filed by funds: To elect five (5) director nominees named in the Proxy Statement/Circular, each to serve until the 2026 Annual General Meeting of Shareholders or until his or her qualified successor has been duly elected or appointed: Joseph Bishop
ARBUTUS BIOPHARMA CORP.’s own tally for this item (“Elect Director: Joseph Bishop”): 122,059,590 for, 8,056,267 withheld, per its Form 8-K filed May 23, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 94% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 36 asset managers below reported 26,569,049 for, 1,314,204 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 8,631,006 | 0 | 0 | 0 | For |
| Morgan Stanley | 6,930,243 | 0 | 0 | 0 | For |
| BlackRock | 5,196,383 | 0 | 0 | 0 | For |
| Fidelity | 2,222,747 | 0 | 0 | 14,095 | For |
| Equitable | 1,452,524 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 0 | 0 | 1,196,192 | Withhold |
| State Street | 643,580 | 0 | 0 | 0 | For |
| Aberdeen | 342,379 | 0 | 0 | 0 | For |
| TIAA | 311,173 | 0 | 0 | 0 | For |
| Lincoln Financial | 195,576 | 0 | 0 | 0 | For |
| Global X | 0 | 0 | 0 | 87,217 | Withhold |
| Goldman Sachs | 76,152 | 0 | 0 | 0 | For |
| Northern Trust | 75,333 | 0 | 0 | 0 | For |
| ProShares | 59,347 | 0 | 0 | 0 | For |
| John Hancock | 55,637 | 0 | 0 | 0 | For |
| Pacific Life | 48,221 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 43,209 | 0 | 0 | 0 | For |
| Voya | 40,720 | 0 | 0 | 0 | For |
| Invesco | 34,997 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 32,553 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 32,123 | 0 | 0 | 0 | For |
| DWS | 21,153 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 21,061 | 0 | 0 | 0 | For |
| Nationwide | 21,049 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 17,801 | 0 | 0 | 0 | For |
Showing the 25 largest of 36 asset managers. All 36 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
95% Majority: yes · of votes cast
Description as filed by funds: To elect five (5) director nominees named in the Proxy Statement/Circular, each to serve until the 2026 Annual General Meeting of Shareholders or until his or her qualified successor has been duly elected or appointed: Lindsay Androski, JD, MBA, CFA
ARBUTUS BIOPHARMA CORP.’s own tally for this item (“Elect Director: Lindsay Androski, JD, MBA, CFA”): 123,784,223 for, 6,331,634 withheld, per its Form 8-K filed May 23, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 95% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 36 asset managers below reported 27,841,928 for, 41,325 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 8,631,006 | 0 | 0 | 0 | For |
| Morgan Stanley | 6,930,243 | 0 | 0 | 0 | For |
| BlackRock | 5,196,383 | 0 | 0 | 0 | For |
| Fidelity | 2,236,842 | 0 | 0 | 0 | For |
| Equitable | 1,452,524 | 0 | 0 | 0 | For |
| Charles Schwab | 1,196,192 | 0 | 0 | 0 | For |
| State Street | 643,580 | 0 | 0 | 0 | For |
| Aberdeen | 342,379 | 0 | 0 | 0 | For |
| TIAA | 311,173 | 0 | 0 | 0 | For |
| Lincoln Financial | 195,576 | 0 | 0 | 0 | For |
| Global X | 87,217 | 0 | 0 | 0 | For |
| Goldman Sachs | 76,152 | 0 | 0 | 0 | For |
| Northern Trust | 75,333 | 0 | 0 | 0 | For |
| ProShares | 59,347 | 0 | 0 | 0 | For |
| John Hancock | 55,637 | 0 | 0 | 0 | For |
| Pacific Life | 48,221 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 43,209 | 0 | 0 | 0 | For |
| Voya | 0 | 0 | 0 | 40,720 | Withhold |
| Invesco | 34,997 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 32,553 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 32,123 | 0 | 0 | 0 | For |
| DWS | 21,153 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 21,061 | 0 | 0 | 0 | For |
| Nationwide | 21,049 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 17,801 | 0 | 0 | 0 | For |
Showing the 25 largest of 36 asset managers. All 36 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
94% Majority: yes · of votes cast
Description as filed by funds: To elect five (5) director nominees named in the Proxy Statement/Circular, each to serve until the 2026 Annual General Meeting of Shareholders or until his or her qualified successor has been duly elected or appointed: Matthew Gline
ARBUTUS BIOPHARMA CORP.’s own tally for this item (“Elect Director: Matthew Gline”): 122,656,045 for, 7,459,812 withheld, per its Form 8-K filed May 23, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 94% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 36 asset managers below reported 26,569,049 for, 1,314,204 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 8,631,006 | 0 | 0 | 0 | For |
| Morgan Stanley | 6,930,243 | 0 | 0 | 0 | For |
| BlackRock | 5,196,383 | 0 | 0 | 0 | For |
| Fidelity | 2,222,747 | 0 | 0 | 14,095 | For |
| Equitable | 1,452,524 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 0 | 0 | 1,196,192 | Withhold |
| State Street | 643,580 | 0 | 0 | 0 | For |
| Aberdeen | 342,379 | 0 | 0 | 0 | For |
| TIAA | 311,173 | 0 | 0 | 0 | For |
| Lincoln Financial | 195,576 | 0 | 0 | 0 | For |
| Global X | 0 | 0 | 0 | 87,217 | Withhold |
| Goldman Sachs | 76,152 | 0 | 0 | 0 | For |
| Northern Trust | 75,333 | 0 | 0 | 0 | For |
| ProShares | 59,347 | 0 | 0 | 0 | For |
| John Hancock | 55,637 | 0 | 0 | 0 | For |
| Pacific Life | 48,221 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 43,209 | 0 | 0 | 0 | For |
| Voya | 40,720 | 0 | 0 | 0 | For |
| Invesco | 34,997 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 32,553 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 32,123 | 0 | 0 | 0 | For |
| DWS | 21,153 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 21,061 | 0 | 0 | 0 | For |
| Nationwide | 21,049 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 17,801 | 0 | 0 | 0 | For |
Showing the 25 largest of 36 asset managers. All 36 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Description as filed by funds: To elect five (5) director nominees named in the Proxy Statement/Circular, each to serve until the 2026 Annual General Meeting of Shareholders or until his or her qualified successor has been duly elected or appointed: Robert Alan Beardsley
ARBUTUS BIOPHARMA CORP.’s own tally for this item (“Elect Director: Robert Alan Beardsley”): 124,837,983 for, 5,277,874 withheld, per its Form 8-K filed May 23, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 36 asset managers below reported 27,883,253 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 8,631,006 | 0 | 0 | 0 | For |
| Morgan Stanley | 6,930,243 | 0 | 0 | 0 | For |
| BlackRock | 5,196,383 | 0 | 0 | 0 | For |
| Fidelity | 2,236,842 | 0 | 0 | 0 | For |
| Equitable | 1,452,524 | 0 | 0 | 0 | For |
| Charles Schwab | 1,196,192 | 0 | 0 | 0 | For |
| State Street | 643,580 | 0 | 0 | 0 | For |
| Aberdeen | 342,379 | 0 | 0 | 0 | For |
| TIAA | 311,173 | 0 | 0 | 0 | For |
| Lincoln Financial | 195,576 | 0 | 0 | 0 | For |
| Global X | 87,217 | 0 | 0 | 0 | For |
| Goldman Sachs | 76,152 | 0 | 0 | 0 | For |
| Northern Trust | 75,333 | 0 | 0 | 0 | For |
| ProShares | 59,347 | 0 | 0 | 0 | For |
| John Hancock | 55,637 | 0 | 0 | 0 | For |
| Pacific Life | 48,221 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 43,209 | 0 | 0 | 0 | For |
| Voya | 40,720 | 0 | 0 | 0 | For |
| Invesco | 34,997 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 32,553 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 32,123 | 0 | 0 | 0 | For |
| DWS | 21,153 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 21,061 | 0 | 0 | 0 | For |
| Nationwide | 21,049 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 17,801 | 0 | 0 | 0 | For |
Showing the 25 largest of 36 asset managers. All 36 are in the interactive database (link above).
Combines 7 wordings of this item as funds reported it.
95% Approved · of votes cast
Prior year: 88.0% for (May 22, 2024 meeting) ▲ 6.6 pts
Description as filed by funds: To approve, on a non-binding advisory basis, the compensation of our named executive officers as disclosed in the Proxy Statement/Circular; and
ARBUTUS BIOPHARMA CORP.’s own tally for this item (“2. Approved, by non-binding advisory vote, the compensation of the Company's named executive officers as disclosed in the Company's Management Proxy Circular and Proxy Statement for the Meeting filed with the Securities ”): 122,791,749 for, 6,976,561 against — passed, per its Form 8-K filed May 23, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “(2) approved, by non-binding advisory vote, the compensation of the Company's named executive officers as disclosed in the Company's Management Proxy Circular and Proxy Statement for the Meeting filed with the Securities and Exchange Commission on April 4, 2025 (the "Proxy Statement/Circular")”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 8,631,006 | 0 | 0 | 0 | For |
| Morgan Stanley | 6,930,243 | 0 | 0 | 0 | For |
| BlackRock | 5,196,383 | 0 | 0 | 0 | For |
| Fidelity | 2,236,842 | 0 | 0 | 0 | For |
| Equitable | 1,452,524 | 0 | 0 | 0 | For |
| Charles Schwab | 1,196,192 | 0 | 0 | 0 | For |
| State Street | 643,580 | 0 | 0 | 0 | For |
| Aberdeen | 0 | 342,379 | 0 | 0 | Against |
| TIAA | 311,173 | 0 | 0 | 0 | For |
| Saba Capital Income & Opportunities Fund | 188,510 | 20,341 | 0 | 1,017 | Mixed |
| Lincoln Financial | 195,576 | 0 | 0 | 0 | For |
| Saba Capital Income & Opportunities Fund II | 105,907 | 11,427 | 0 | 572 | Mixed |
| Global X | 87,217 | 0 | 0 | 0 | For |
| Goldman Sachs | 76,152 | 0 | 0 | 0 | For |
| Northern Trust | 75,333 | 0 | 0 | 0 | For |
| ProShares | 59,347 | 0 | 0 | 0 | For |
| John Hancock | 55,637 | 0 | 0 | 0 | For |
| Pacific Life | 48,221 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 43,209 | 0 | 0 | 0 | For |
| Voya | 40,720 | 0 | 0 | 0 | For |
| Invesco | 0 | 34,997 | 0 | 0 | Against |
| Direxion Shares ETF Trust | 32,553 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 32,123 | 0 | 0 | 0 | For |
| DWS | 21,153 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 21,061 | 0 | 0 | 0 | For |
Fund voting reports, all 38 managers: 27,786,808 for, 422,630 against, 1,589 withheld. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Morgan Stanley | 22,119,980 | 0 | 0 | 0 | For |
| Whitefort Capital Management, LP | 13,307,967 | 0 | 0 | 0 | For |
| Two Seas Capital LP | 9,272,555 | 0 | 0 | 0 | For |
| BlackRock | 3,295,587 | 54,827 | 0 | 0 | For |
| Woodline Partners LP | 2,552,942 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 2,195,711 | 0 | 0 | 0 | For |
| State Street | 2,155,368 | 1,481 | 0 | 0 | For |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 1,575,941 | 0 | 0 | 0 | For |
| Rangeley Capital, LLC | 1,349,000 | 0 | 0 | 0 | For |
| Charles Schwab | 1,196,432 | 0 | 0 | 0 | For |
| Saba Capital Management, L.P. | 925,416 | 31,768 | 1,589 | 0 | For |
| Rubric Capital Management LP | 827,328 | 0 | 0 | 0 | For |
| Northern Trust | 724,242 | 0 | 0 | 0 | For |
| Hudson Bay Capital Management LP | 484,461 | 0 | 0 | 0 | For |
| Vanguard | 480,513 | 0 | 0 | 0 | For |
| ADAR1 Capital Management, LLC | 454,920 | 0 | 0 | 0 | For |
| Wellington | 370,538 | 0 | 0 | 0 | For |
| Aberdeen | 0 | 342,379 | 0 | 0 | Against |
| Nuveen | 313,307 | 0 | 0 | 0 | For |
| PARAMETRIC PORTFOLIO ASSOCIATES LLC | 294,758 | 0 | 0 | 0 | For |
| UBS | 0 | 267,277 | 0 | 0 | Against |
| MELLON INVESTMENTS Corp | 214,029 | 0 | 0 | 0 | For |
| KENNEDY CAPITAL MANAGEMENT LLC | 147,860 | 33,734 | 0 | 0 | Mixed |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 122,042 | 0 | 0 | 0 | For |
| AllianceBernstein | 120,240 | 0 | 0 | 0 | For |
Institutional-manager reports, all 113 managers: 65,673,637 for, 962,139 against, 1,824 abstained. Showing the 25 largest; every one is in the interactive database (link above).
99.7% Approved · of votes cast
Description as filed by funds: To approve the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025.
ARBUTUS BIOPHARMA CORP.’s own tally for this item (“3. To approve the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025”): 157,702,833 for, 486,002 against — passed, per its Form 8-K filed May 23, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “(3) approved the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025”
Support: 99.7% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 38 asset managers below reported 28,209,799 for, 1,081 against, 148 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 8,631,006 | 0 | 0 | 0 | For |
| Morgan Stanley | 6,930,243 | 0 | 0 | 0 | For |
| BlackRock | 5,196,383 | 0 | 0 | 0 | For |
| Fidelity | 2,236,842 | 0 | 0 | 0 | For |
| Equitable | 1,452,524 | 0 | 0 | 0 | For |
| Charles Schwab | 1,196,192 | 0 | 0 | 0 | For |
| State Street | 643,580 | 0 | 0 | 0 | For |
| Aberdeen | 342,379 | 0 | 0 | 0 | For |
| TIAA | 311,173 | 0 | 0 | 0 | For |
| Saba Capital Income & Opportunities Fund | 209,082 | 692 | 0 | 95 | For |
| Lincoln Financial | 195,576 | 0 | 0 | 0 | For |
| Saba Capital Income & Opportunities Fund II | 117,464 | 389 | 0 | 53 | For |
| Global X | 87,217 | 0 | 0 | 0 | For |
| Goldman Sachs | 76,152 | 0 | 0 | 0 | For |
| Northern Trust | 75,333 | 0 | 0 | 0 | For |
| ProShares | 59,347 | 0 | 0 | 0 | For |
| John Hancock | 55,637 | 0 | 0 | 0 | For |
| Pacific Life | 48,221 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 43,209 | 0 | 0 | 0 | For |
| Voya | 40,720 | 0 | 0 | 0 | For |
| Invesco | 34,997 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 32,553 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 32,123 | 0 | 0 | 0 | For |
| DWS | 21,153 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 21,061 | 0 | 0 | 0 | For |
Showing the 25 largest of 38 asset managers. All 38 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 191,527,129 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 4.51% |
| 2 | Morgan Stanley | 3.62% |
| 3 | BlackRock | 2.71% |
| 4 | Fidelity | 1.17% |
| 5 | Equitable | 0.76% |
| 6 | Charles Schwab | 0.62% |
| 7 | State Street | 0.34% |
| 8 | Aberdeen | 0.18% |
| 9 | TIAA | 0.16% |
| 10 | Saba Capital Income & Opportunities Fund | 0.11% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Morgan Stanley | 11.55% |
| 2 | Whitefort Capital Management, LP | 6.95% |
| 3 | Two Seas Capital LP | 4.84% |
| 4 | BlackRock | 1.75% |
| 5 | Woodline Partners LP | 1.33% |
| 6 | GEODE CAPITAL MANAGEMENT, LLC | 1.15% |
| 7 | State Street | 1.13% |
| 8 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 0.82% |
| 9 | Rangeley Capital, LLC | 0.70% |
| 10 | Charles Schwab | 0.62% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| Matthew Gline | 38,847,462 | 20.28% | Proxy statement (DEF 14A), proxy filed April 4, 2025 |
| Roivant Sciences Ltd. | 38,847,462 | 20.28% | Schedule 13D, filed February 25, 2025 |
| Morgan Stanley | 25,910,337 | 13.53% | Schedule 13G, filed February 11, 2026 |
| Two Seas Capital LP | 18,557,543 | 9.69% | Schedule 13G, filed May 15, 2026 |
| Whitefort Capital Master Fund, LP | 15,794,261 | 8.25% | Schedule 13D, filed April 28, 2026 |
| Whitefort Capital Management, LP | 13,307,967 | 6.95% | Proxy statement (DEF 14A), proxy filed April 4, 2025 |
| BlackRock | 12,766,622 | 6.67% | Form 13F, quarter ended March 31, 2025 |
| Vanguard Group | 8,953,823 | 4.67% | Form 13F, quarter ended March 31, 2025 |
| State Street | 4,363,507 | 2.28% | Form 13F, quarter ended March 31, 2025 |
| Michael J. McElhaugh | 2,649,793 | 1.38% | Proxy statement (DEF 14A), proxy filed April 4, 2025 |
Percentages above are of 191,527,129 shares outstanding, as reported by ARBUTUS BIOPHARMA CORP. on its Form 10-Q dated May 12, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At ARBUTUS BIOPHARMA CORP.'s shareholder meeting held May 21, 2025, in the 2024-2025 proxy season, 137 asset managers reported votes on at least one of its 7 ballot items in their SEC Form N-PX filings, covering 998 separate fund positions. On the most widely held item on that ballot — To approve, on a non-binding advisory basis, the compensation of our named executive officers… — ARBUTUS BIOPHARMA CORP.'s filing reports the proposal as approved, with 95% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: ARBUTUS BIOPHARMA CORP.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 23, 2025.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ARBUTUS BIOPHARMA CORP.’s 10-Q dated May 12, 2025. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
ARBUTUS BIOPHARMA CORP. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.
Proxy Votes Now, “ARBUTUS BIOPHARMA (ABUS) 2025 Annual Meeting: Shareholder Vote Results”, https://proxyvotesnow.com/company/arbutus-biopharma-corp/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.